» Articles » PMID: 37270440

Bidirectional Approach with PIPAC and Systemic Chemotherapy for Patients with Synchronous Gastric Cancer Peritoneal Metastases (GCPM)

Abstract

Background: This study evaluated the efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with systemic chemotherapy as a bidirectional approach for gastric cancer (GC) patients with synchronous peritoneal metastases (SPM).

Methods: A retrospective analysis of a prospective PIPAC database was queried for patients who underwent a bidirectional approach between October 2019 and April 2022 at two high-volume GC surgery units in Italy (Verona and Siena). Surgical and oncological outcomes were analyzed.

Results: Between October 2019 and April 2022, 74 PIPAC procedures in 42 consecutive patients with Eastern Cooperative Oncology Group performance status ≤2 were performed-32 patients treated in Verona and 10 in Siena. Twenty-seven patients (64%) were female and median age at first PIPAC was 60.5 years (I-III quartiles: 49-68 years). Median Peritoneal Cancer Index (PCI) was 16 (I-III quartiles: 8-26) and 25 patients (59%) had at least two PIPAC procedures. Major complications according to the Common Terminology Criteria for Adverse Events (CTCAE; 3 and 4) occurred in three (4%) procedures, and, according to the Clavien-Dindo classification (>3a), one (1%) severe complication occurred. There were no reoperations or deaths within 30 days. Median overall survival (mOS) from diagnosis was 19.6 months (range 14-24), and mOS from first PIPAC was 10.5 months (range 7-13). Excluding cases with very heavy metastatic peritoneal burden, with PCI from 2 to 26, treated with more than one PIPAC, mOS from diagnosis was 22 months (range 14-39). Eleven patients (26%) underwent curative-intent surgery after a bidirectional approach. R0 was achieved in nine (82%) patients and complete pathological response was obtained in three (27%) cases.

Conclusions: Patient selection is associated with bidirectional approach efficacy and feasibility for SPM GC treatment, which may allow potentially curative surgical radicalization in highly selected cases.

Citing Articles

Predictive Factors for the Discontinuation of Pressurized Intraperitoneal Aerosol Chemotherapy: Enhancing Patient Selection to Improve Oncological Outcomes-A Single-Center Experience.

Aulicino M, Santullo F, Orsini C, DAgostino L, Hubner M, Texeira-Farinha H Cancers (Basel). 2025; 17(2).

PMID: 39858047 PMC: 11763660. DOI: 10.3390/cancers17020265.


Efficacy and Insights from an Extensive Series of Cytoreductive Surgery for Peritoneal Neoplasms: A High-Volume Single-Center Experience.

Aulicino M, Santullo F, DAnnibale G, Abatini C, Attalla El Halabieh M, Orsini C Cancers (Basel). 2025; 16(24.

PMID: 39766128 PMC: 11726991. DOI: 10.3390/cancers16244229.


How to Implement Pressurized Intraperitoneal Aerosol Chemotherapy into a National Health System Scenario: A Single-Center Retrospective Analysis of Costs and Economic Sustainability at a High-Volume Italian Hospital.

Aulicino M, Orsini C, DAnnibale G, Barberis L, Catania P, Abatini C Cancers (Basel). 2024; 16(15).

PMID: 39123365 PMC: 11312094. DOI: 10.3390/cancers16152637.


Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis.

Guchelaar N, Nasserinejad K, Mostert B, Koolen S, van der Sluis P, Lagarde S Br J Surg. 2024; 111(5).

PMID: 38722803 PMC: 11081074. DOI: 10.1093/bjs/znae116.


Peritoneal Metastatic Gastric Cancer: Local Treatment Options and Recommendations.

Acs M, Piso P, Glockzin G Curr Oncol. 2024; 31(3):1445-1459.

PMID: 38534942 PMC: 10969192. DOI: 10.3390/curroncol31030109.

References
1.
Tempfer C, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek G . A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol. 2018; 150(1):23-30. DOI: 10.1016/j.ygyno.2018.05.001. View

2.
Di Giorgio A, Schena C, Attalla El Halabieh M, Abatini C, Vita E, Strippoli A . Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis. Surg Oncol. 2020; 34:270-275. DOI: 10.1016/j.suronc.2020.05.006. View

3.
Giger-Pabst U, Tempfer C . How to Perform Safe and Technically Optimized Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of 1200 Procedures. J Gastrointest Surg. 2018; 22(12):2187-2193. DOI: 10.1007/s11605-018-3916-5. View

4.
Gockel I, Jansen-Winkeln B, Haase L, Rhode P, Mehdorn M, Niebisch S . Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Cancer Patients with Peritoneal Metastasis (PM): Results of a Single-Center Experience and Register Study. J Gastric Cancer. 2019; 18(4):379-391. PMC: 6310762. DOI: 10.5230/jgc.2018.18.e37. View

5.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View